MDX-11 monoclonal antibody data

MEDX announced results of a multi-center Phase I/II trial in 16 patients, showing on average a 90 percent reduction in circulating leukemia cells in half the patients, but only a transient effect on the reduction in tumor burden. As reported at the International Conference on Bone Marrow Transplantation in Beijing, no human anti-mouse antibody reactions were noted, but two patients had antibody-related toxicities that required withdrawal from therapy. The reactions were reversed by appropriate treatment, the company said.

MEDX plans to start a Phase II trial in a few weeks, to test the ability of MDX-11 to eliminate residual cancer cells following standard chemotherapy. ...